/Investor DB

Novartis Venture Fund — 2021 Investments

5 investments dated 2021 · listed companies and verified rows first · show all

Soteria Biotherapeutics, Inc.soteriabiotherapeutics.cominMay 2021✓ verified

Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.

BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Jim Wells(Co-founder, Scientific Advisory Board Chair)Kristine M Ball(Executive Officer, Director)inZachary Hill(Executive Officer, Director)in

BoardNisha Marathe(Director)David Allison(Director)inKeno Gutierrez(Director)in

Co-investors5AM VenturesRoche Venture FundVersant VenturesBioGeneration VenturesWestlake Village BioPartners

Amphista Therapeuticsamphista.comin𝕏Series B · Mar 2021 · $53M

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in

Co-investorsAdvent Life SciencesSV Health InvestorsDementia Discovery FundEuropean Investment FundForbionGilde Healthcare+2 more

Immunitas Therapeuticsimmunitastx.cominAug 2021

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(CEO)inDan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

BoardLaura Brass(Director)inKai Wucherpfennig(Director)

Co-investorsAgent CapitalDC Investment PartnersLifelinkLongwood FundM VenturesMedical Excellence Capital+5 more

LoQus23loqus23.cominSeed · Nov 2021 · $9M

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in

Co-investorsDementia Discovery FundSV Health InvestorsForbion

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Expansion Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.